ERBB2 and breast carcinoma: A novel cancer-specific anti-HER2 antibody, H2Mab-250/H2CasMab-2 (IgG1, kappa), which exhibits high reactivity to HER2-positive breast cancer tissues without affecting normal tissues, has been developed (111).